Abeona Therapeutics (ABEO) Stock Price, Quote & News

Company Profile

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is pz-cel, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based g...

Industry: Biotechnology

Sector: Healthcare

Phone: 646 813 4701

Website: www.abeonatherapeutics.com

Address:

6555 Carnegie Avenue, 4th Floor, Cleveland, United States

TimeForBio Oct. 7 at 4:03 AM

$ABEO According to Taysha, the Breakthrough Therapy Designation may accelerate the BLA submission for TSHA-102 by at least two quarters, opening the door for a 2026 filing(!) Analyst projections estimate peak revenue of around $2.2 billion. Given Abeona’s 8% ("high single-digit royalty") share of net sales, this translates to approximately $176M in potential revenue.

0 · Reply

TimeForBio Oct. 7 at 3:26 AM

$ABEO I’m disappointed by the lack of press releases on two highly important milestones: * The first patient treated with ZEVASKYN (pz-cel). * FDA Breakthrough Therapy Designation for TSHA-102. Both of these are material events that investors deserve to be informed about. Timely updates not only build trust with shareholders but also help support the company’s share price by ensuring that the market fully understands Abeona’s progress. I encourage all fellow shareholders to reach out to Abeona’s Investor Relations team and let them know that we, as investors, expect clear and timely communication on such developments.

2 · Reply

Po556677 Oct. 7 at 12:10 AM

$ABEO NANTAHALA CAPITAL PARTNERS LIMITED PARTNERSHIP has acquired over 2 million shares per the 13g filing......ABEO is being accumulated/shorts beware!!

0 · Reply

Buyorsell4321 Oct. 6 at 11:53 PM

$ABEO another 13g tonight 👀

1 · Reply

qqre Oct. 6 at 7:34 PM

$ABEO As expected, the stock is trading lower today, and we're deep in thought after seeing the post below about a possible Q3 treatment failure

1 · Reply

creditgoo Oct. 6 at 7:19 PM

$ABEO again this a perfect spot for dead money

0 · Reply

kenny91655 Oct. 6 at 6:47 PM

$ABEO Spruce Sanfillipo. Crazy action

1 · Reply

FitzCatalyst Oct. 6 at 5:40 PM

$ABEO disappointing

0 · Reply

creditgoo Oct. 6 at 5:37 PM

$ABEO only red on my list in over 800 tickers

1 · Reply

creditgoo Oct. 6 at 2:58 PM

$ABEO loaded more puts today

1 · Reply

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 29, 2025, 7:30 AM EDT - 5 weeks ago

Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences

Aug 19, 2025, 3:25 PM EDT - 6 weeks ago

Abeona Therapeutics Inc. (ABEO) Q2 2025 Earnings Call Transcript

Aug 15, 2025, 4:36 PM EDT - 7 weeks ago

Abeona Therapeutics: AAV204 Capsid Could Be Next Growth Prospect Beyond Zevaskyn

Aug 14, 2025, 7:30 AM EDT - 7 weeks ago

Abeona Therapeutics® Reports Second Quarter 2025 Financial Results and Corporate Updates

Jul 29, 2025, 10:00 AM EDT - 2 months ago

AscellaHealth HUB Partnership with Abeona Therapeutics® Supports Launch Success of Novel Cell-Based Gene Therapy and Access to Treatment for Rare Disease Patients

Jul 15, 2025, 7:30 AM EDT - 2 months ago

ZEVASKYN™ Gene Therapy Now Available at New Qualified Treatment Center in San Francisco Bay Area

Jul 14, 2025, 7:00 AM EDT - 3 months ago

Bio-Techne's Simple Western™ Technology Utilized in Recent FDA Approval of ZEVASKYN™ Cell-Based Gene Therapy

TECH

Jul 2, 2025, 7:30 AM EDT - 3 months ago

Abeona Therapeutics® Closes Sale of Rare Pediatric Disease Priority Review Voucher for $155 Million

Jul 1, 2025, 7:30 AM EDT - 3 months ago

Abeona Therapeutics® Announces Option Exercise by Beacon Therapeutics for Novel AAV204 Capsid for Ophthalmology Gene Therapy

Jun 30, 2025, 7:30 AM EDT - 3 months ago

Abeona Therapeutics® added to Membership of U.S. Small-cap Russell 2000® Index and Broad-market Russell 3000® Index

Jun 24, 2025, 7:30 AM EDT - 3 months ago

Abeona Therapeutics® Announces Publication in The Lancet of Phase 3 VIITAL™ Study Data in Recessive Dystrophic Epidermolysis Bullosa

Jun 5, 2025, 5:48 AM EDT - 4 months ago

Abeona Therapeutics: Substantially Undervalued Post-FDA Approval (Rating Upgrade)

May 30, 2025, 8:46 AM EDT - 4 months ago

Abeona Therapeutics® to Present at the Jefferies Global Healthcare Conference

May 16, 2025, 1:37 AM EDT - 5 months ago

Abeona Therapeutics Inc. (ABEO) Q1 2025 Earnings Call Transcript

May 15, 2025, 7:30 AM EDT - 5 months ago

Abeona Therapeutics® Reports First Quarter 2025 Financial Results and Corporate Updates

May 14, 2025, 8:07 AM EDT - 5 months ago

UPDATE -- Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin Disorder

May 14, 2025, 7:30 AM EDT - 5 months ago

Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYNTM Gene Therapy to Treat Wounds in Painful Skin Disorder

May 14, 2025, 7:30 AM EDT - 5 months ago

Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin Disorder

May 12, 2025, 7:30 AM EDT - 5 months ago

Abeona Therapeutics® Enters into Agreement to Sell Priority Review Voucher for $155 Million

Apr 30, 2025, 4:41 PM EDT - 5 months ago

Abeona Surges After FDA Clears First Gene Therapy For Severe Genetic Skin Disease

Apr 29, 2025, 6:06 AM EDT - 5 months ago

US FDA approves Abeona's skin disorder therapy

Apr 29, 2025, 6:00 AM EDT - 5 months ago

U.S. FDA Approves ZEVASKYN™ (prademagene zamikeracel), the First and Only Cell-Based Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Apr 27, 2025, 8:30 AM EDT - 5 months ago

Undercovered Dozen: 3D Systems, Seritage, Topicus, Timken +

DDD TKR KARO NNDM ORC PAA PAGP

Apr 21, 2025, 10:00 AM EDT - 6 months ago

Pz-Cel Has Massive Potential For RDEB Patients

Apr 12, 2025, 11:39 AM EDT - 6 months ago

Abeona Therapeutics: A Buy With Major PDUFA Catalyst On April 29 That Should Send Shares Higher

Mar 20, 2025, 3:20 PM EDT - 7 months ago

Abeona Therapeutics Inc. (ABEO) Q4 2024 Earnings Call Transcript

Mar 20, 2025, 7:30 AM EDT - 7 months ago

Abeona Therapeutics® Reports Full Year 2024 Financial Results, Provides Pz-cel Regulatory Update and Commercial Launch Plans

Mar 4, 2025, 9:00 AM EST - 7 months ago

Abeona Therapeutics® to Present at the Leerink Partners Global Healthcare Conference

Jan 24, 2025, 12:40 PM EST - 9 months ago

Abeona Therapeutics: Despite Some Competitive Pressure, This Looks Undervalued

Nov 14, 2024, 7:30 AM EST - 11 months ago

Abeona Therapeutics® Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

Nov 12, 2024, 7:30 AM EST - 11 months ago

Abeona Therapeutics® Announces FDA Acceptance of BLA Resubmission of Pz-cel for the Treatment of Recessive Dystrophic Epidermolysis Bullosa

Nov 4, 2024, 7:30 AM EST - 1 year ago

Abeona Therapeutics® Announces Participation in November Investor Conferences

Oct 29, 2024, 7:30 AM EDT - 1 year ago

Abeona Therapeutics® Completes Pz-cel Biologics License Application Resubmission to U.S. Food and Drug Administration

Oct 3, 2024, 8:09 AM EDT - 1 year ago

Abeona Therapeutics Targets RDEB Market With Promising Pz-cel Therapy

Aug 14, 2024, 7:30 AM EDT - 1 year ago

Abeona Therapeutics® Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD to its Board of Directors

Aug 13, 2024, 7:30 AM EDT - 1 year ago

Abeona Therapeutics® Announces Favorable Medicare Reimbursement Decisions for Pz-cel

Aug 12, 2024, 7:30 AM EDT - 1 year ago

Abeona Therapeutics® Reports Second Quarter 2024 Financial Results and Concludes Type A Meeting with FDA to Align on Upcoming Pz-cel BLA Resubmission

Jul 12, 2024, 4:59 PM EDT - 1 year ago

Abeona: BLA Resubmission Of Pz-Cel Gets Ball Rolling Towards Other Milestones

Jul 11, 2024, 7:30 AM EDT - 1 year ago

Abeona Therapeutics and Beacon Therapeutics Announce Non-Exclusive Agreement for Beacon to Evaluate Therapeutic Potential of Abeona's Patented AAV204 Capsid for Select Ophthalmology Indications

Jul 8, 2024, 7:30 AM EDT - 1 year ago

Abeona Therapeutics to Present at the Stifel Virtual Cell Therapy Forum

Jun 3, 2024, 7:30 AM EDT - 1 year ago

Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 28, 2024, 7:30 AM EDT - 1 year ago

Abeona Therapeutics to Present at the Jefferies Global Healthcare Conference

May 15, 2024, 7:30 AM EDT - 1 year ago

Abeona Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Progress

May 3, 2024, 7:30 AM EDT - 1 year ago

Abeona Therapeutics Announces Pricing of $75 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

May 2, 2024, 5:50 PM EDT - 1 year ago

Buying The Dip In Abeona Therapeutics After The Recent Manufacturing-Related CRL

May 2, 2024, 11:00 AM EDT - 1 year ago

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Abeona Therapeutics Inc. (ABEO) on Behalf of Investors

TimeForBio Oct. 7 at 4:03 AM

0 · Reply

TimeForBio Oct. 7 at 3:26 AM

2 · Reply

Po556677 Oct. 7 at 12:10 AM

$ABEO NANTAHALA CAPITAL PARTNERS LIMITED PARTNERSHIP has acquired over 2 million shares per the 13g filing......ABEO is being accumulated/shorts beware!!

0 · Reply

Buyorsell4321 Oct. 6 at 11:53 PM

$ABEO another 13g tonight 👀

1 · Reply

qqre Oct. 6 at 7:34 PM

$ABEO As expected, the stock is trading lower today, and we're deep in thought after seeing the post below about a possible Q3 treatment failure

1 · Reply

creditgoo Oct. 6 at 7:19 PM

$ABEO again this a perfect spot for dead money

0 · Reply

kenny91655 Oct. 6 at 6:47 PM

$ABEO Spruce Sanfillipo. Crazy action

1 · Reply

FitzCatalyst Oct. 6 at 5:40 PM

$ABEO disappointing

0 · Reply

creditgoo Oct. 6 at 5:37 PM

$ABEO only red on my list in over 800 tickers

1 · Reply

creditgoo Oct. 6 at 2:58 PM

$ABEO loaded more puts today

1 · Reply

oreoPp Oct. 5 at 3:18 PM

$ABEO bring. The. Balls.

0 · Reply

LiquidThetaLEAPS Oct. 5 at 8:42 AM

LiquidTheta® LEAPS LIVE Actionable Alert Asset: $ABEO Current Share Price: $5.41 Contracts: $ABEO March 20, 2026 $6 Calls Scale in: $1.54- $1.88 Scale out: $2.39-$3.07 Can Easily Capture: 60% ROI Blended DTE: 168 Days | Join Elites here: https://liquidtheta.com/options

0 · Reply

stick_to_stocks Oct. 4 at 9:58 AM

$ABEO continuous slaps. They know it will go up

0 · Reply

alexpitti Oct. 3 at 11:23 PM

another 2 weeks in the books. i have an ear infection, but i should be healthy in 2-3 days huge data from $AUTL coming in october huge approvals for $STXS in October GenesisX & EMAGIN 5F & MAGiC Sweep ESMO in 2 weeks for $DCTH hopefully we can get the first procedure announced next week $ABEO kinda in no man's land right now

3 · Reply

xelaxela Oct. 3 at 9:23 PM

$ABEO Just loaded the boat. Lets see if we can get some action.

0 · Reply

oreoPp Oct. 3 at 5:44 PM

$ABEO CEO said. We. Will. Be. Profit able next. Year.

0 · Reply

creditgoo Oct. 3 at 5:00 PM

$ABEO bio stocks are trash. Legit every stock is up 100% in the last month except bios

0 · Reply

S144 Oct. 3 at 1:28 PM

$ABEO Taysha Gene Therapies (TSHA) jumped 53% after the U.S. FDA granted its Breakthrough Therapy designation for the company's lead candidate TSHA-102 as a treatment for Rett syndrome, a rare neurodevelopmental disorder.

0 · Reply

fede5910 Oct. 3 at 1:13 PM

$ABEO This seems like a good time for the company to buy shares in the market. What better investment than in their own business. They know where they are and where they are going. I understand this could be a guaranteed profit.

0 · Reply

ExtraRun123 Oct. 3 at 12:07 PM

$ABEO It won't drop below $5, forget it. The current valuation is ridiculous and should be fixed soon. You're not very smart if you don't buy now. Abeona should be valued above its current MC just based on cash + royalties.

2 · Reply

Filvul Oct. 3 at 8:50 AM

$ABEO Manufacturing failure would explain lack of Q3 2025 revenue... The silence on first patient treatment, combined with industry manufacturing failure rates and ZEVASKYN's complexity, suggests a significant probability (60-70%) that manufacturing challenges have occurred. :/

4 · Reply

heyupikachu1821 Oct. 2 at 8:17 PM

$LQDA $SRPT $SLNO $ABEO $MLTX These are all at extreme lows that I whole heartedly believe they will bounce back from Each has dropped for its own reason. Each comes with its own risk. Each will likely take time to recover But at these prices, the risk / reward is worth considering if you have the patience to go for a longer-term swing

0 · Reply

Market Cap	277.42M
Revenue (ttm)	0.00
Net Income (ttm)	-63.73M
EPS (ttm)	N/A
PE Ratio	5.78
Forward PE	4.10
Profit Margin	0.00%
Debt to Equity Ratio	0.12

Volume	693,900
Avg Vol	825,290
Day's Range	N/A - N/A
Shares Out	51.28M
Stochastic %K	34%
Beta	1.42
Analysts	Strong Sell
Price Target	$20.50